Advertisement
Advertisement
U.S. markets open in 9 hours 3 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Y-mAbs Therapeutics, Inc. (YMAB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.99+0.77 (+7.53%)
At close: 04:00PM EST
10.99 0.00 (0.00%)
After hours: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close10.22
Open9.78
Bid10.95 x 800
Ask15.88 x 900
Day's Range9.70 - 11.14
52 Week Range9.70 - 50.70
Volume565,219
Avg. Volume275,878
Market Cap479.646M
Beta (5Y Monthly)1.11
PE Ratio (TTM)N/A
EPS (TTM)-0.90
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for YMAB

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Y-mAbs Therapeutics, Inc.
    Weekly Stock ListIn our view, the Life Sciences segment of the U.S. Healthcare industry is poised for strong growth over the next few years. This is the part of the industry that is developing the next generation of gene therapies, oncology biologics, and vaccines. Gene therapy holds promise for many diseases, but today serves only as an alternative treatment for some rare diseases. After a period of stagnation, gene therapy has experienced a renaissance, due largely to significant advances in technology and manufacturing scale. Scientists have developed safer, more-efficient viral vectors with better targeting capability. As such, the future for gene therapy appears bright. Currently, there are approximately 400 ongoing gene-therapy clinical trials, and we expect to see new gene therapies gain regulatory approval in the years ahead. This is critically important for patients and patient communities who are waiting for therapeutic advances to treat unmet genetic diseases. In the Argus Universe of Coverage, the following companies are among those that are involved in this part of the Healthcare market. All of them carry an Argus BUY rating.
    Rating
    Fair Value
    Economic Moat
    29 days agoArgus Research
View more
  • Simply Wall St.

    Investors one-year losses grow to 76% as the stock sheds US$69m this past week

    It's not a secret that every investor will make bad investments, from time to time. But it's not unreasonable to try to...

  • GlobeNewswire

    Y-mAbs Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

    NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that its Chief Executive Officer, Dr. Claus Moller, MD, Ph.D., will provide an overview and update on the Company's business at the virtual 40th Annual J.P. Morgan Healthcare Conference. The presentatio

  • GlobeNewswire

    UPDATE - Y-mAbs Announces Pipeline Update

    NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that clinical experience for naxitamab and data from the Company’s SADA technology programs will be presented at the Company’s R&D event, which will take place virtually today at 12 p.m. Eastern Time. I

Advertisement
Advertisement